Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Transcription factor alterations in AML and risk: RUNX, CEPBA & EVI1

Ruud Delwel • 15 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Ruud Delwel, PhD, of the Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, discusses transcription factor alterations in acute myeloid leukemia (AML), and how these affect disease risk and response to treatment. Dr Delwel covers RUNX1, C/EBPα, and EVI1, which is a key focus of his lab. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Ruud Delwel

2:06
EVI1 alteration in AML: mechanisms, disease risk & potential targeting
Ruud Delwel • 14 Mar 2019

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals